SGS FY25 Results Rise, Sees Sales Growth In FY26, Confirms FY27 View

SGS reported fiscal 2025 profit attributable to equity holders of CHF 668m, up 15% from CHF 581m, with basic EPS of CHF 3.48 (+12.3%). Revenue rose to CHF 6.95bn (+2.2% YoY) with 5.6% organic growth; operating income was CHF 1.01bn (+12.2%) and adjusted operating income CHF 1.11bn (+6.5%) as AOI margin improved to 16% from 15.3%. The board will propose maintaining the dividend at CHF 3.20/share, and management guided FY2026 organic sales growth of 5–7% plus 5–7% from acquisitions (including ATS) with AOI margin in line with or above 16%, reconfirming a 2027 target of 5–7% annual organic growth and at least a 1.5pp AOI margin improvement vs 2023.

Analysis

Market structure: SGS (SGSOY.PK) is the clear near-term beneficiary — guidance of 5–7% organic growth plus 5–7% from acquisitions (including ATS) implies mid-single-digit topline expansion and operating leverage that should pressure peers (Intertek ITRK.L, Bureau Veritas BVI.PA) on market share and pricing. AOI margin target >=16% and a 1.5ppt improvement by 2027 vs 2023 signals improving pricing power and cost synergy capture; services demand (pharma, food, industrial) looks resilient, not cyclical capex-driven. Cross-asset: expect modest CHF appreciation pressure on reported EUR/USD sales, modest tightening of SGS credit spreads (better fundamentals), and lower equity implied vol for SGS as guidance reduces uncertainty.

Risk assessment: tail risks include failed ATS integration (operational/systems mismatch), regulatory hurdles/antitrust on M&A, material HQ disposal tax or one-offs, or a macro slowdown that trims industrial testing volumes >5% YoY. Immediate (days) risk: earnings reaction and guidance re-pricing; short-term (weeks–months): ATS deal terms and Capital Markets Event details; long-term (years): delivery on 1.5ppt margin improvement. Hidden dependency: margin improvement assumes successful cost synergies and stable pricing — if energy or input-testing costs rise 200–300bps, AOI targets are at risk.

Trade implications: establish a tactical overweight in SGS (SGSOY.PK) — consider 2–4% position targeting +12–20% total return over 6–12 months if AOI margin stays >=16% and organic growth meets mid-point 6%. Pair trade: long SGSOY.PK vs short BVI.PA (notional neutral) for 6–12 months to isolate SGS’ execution upside. Options: buy 9–12 month ATM calls (cost cap 0.5–1% of portfolio) to capture upside ahead of Capital Markets Event; hedge M&A dilution risk with 60–120 day puts if ATS financing exceeds 15% equity issuance.

Contrarian angles: consensus may underprice integration and execution risk — market could be overly optimistic about immediate margin accretion; conversely, reaction may be underdone if investors ignore stable dividend (CHF3.20) plus acquisitive growth, creating a mispricing. Historical parallels: past testing-sector rollups delivered front-loaded integration costs and back-loaded margins (Bureau Veritas/Intertek precedents), so watch 2–3 quarter delivery cadence. Unintended consequence: maintaining dividend constrains buybacks and cash for ATS, so a material equity-funded deal (>15% dilution) would be a catalyst for a >10% downside re-rate.

Key Decisions for Investors

• Establish a 2–4% long position in SGS (SGSOY.PK) within 5 trading days; target 12–20% upside over 6–12 months if AOI margin stays >=16% and organic growth hits at least 5.5%; set stop-loss at -8% from entry or exit if company revises organic guidance below 5%.
• Implement a pair trade: go long SGSOY.PK (2%) and short Bureau Veritas (BVI.PA) (1.8% notional) for 6–12 months to capture relative execution on margins; unwind if the spread narrows <200bps or either stock moves >15% intra-period.
• Buy 9–12 month ATM call options on SGSOY.PK sized to 0.5–1% of portfolio capital (expiry ~Jan–Mar 2027) to leverage the Capital Markets Event and expected margin improvement; if implied vol rises >30% premium, switch to a call spread to cap cost.
• Monitor ATS deal finance terms over next 30–90 days: if financing requires >15% equity issuance or acquisition premium >20% EBITDA, hedge by buying 60–120 day SGSOY.PK puts equal to 0.5% portfolio or reduce long to 1% until deal clarity.